Dr. Daniel will test whether blocking an enzyme called GSK3 can lower harmful fibulin-3 levels and help restore healthy tissue structure. By studying cells and animal models, Dr. Daniel will show that correcting this tissue imbalance can improve fluid drainage and reduce eye pressure.

Dr. Choi aims to develop a new therapeutic strategy that corrects the underlying genetic variants responsible for STGD1. Using a highly precise gene-editing tool known as a ‘prime editor,’ he will repair the disease-causing mutations directly within the cells of the retina.

Dr. Cao’s recent research discovered mutations in FSD1L in six patients with early-onset retinitis pigmentosa (RP), indicating FSD1L as a newly IRD associated gene. However, very little is known about the function of FSD1L in the retina or how these genetic changes might lead to degeneration of photoreceptors, the cells responsible for capturing light.

Akron Children’s has received a $2 million research endowment from the Knights Templar Eye Foundation (KTEF) to expand its research in pediatric eye disorders. In tandem with the foundation’s philanthropic support, Akron Children’s will match the gift with an additional $2 million for a total of $4 million.

A $2 million gift from the Knights Templar Eye Foundation, Inc. (KTEF), has forged a partnership with the W.K. Kellogg Eye Center at Michigan Medicine’s Department of Ophthalmology and Visual Sciences, establishing the Knights Templar Eye Foundation Endowed Pediatric Research Fund.

Dr. Zaidi is studying whether Apolipoprotein A1 can reduce inflammation and abnormal blood vessel growth in retinopathy of prematurity. The research could point toward safer ways to protect vision in premature infants.

For the second year in a row, we received more contributions than any previous year. Contributions totaled $1,938,951. That is an increase of $61,357 or 3.3% over the prior Campaign. Two record setting years in a row. The Knights of the Grand Encampment are reaching deep and making a difference in this world.

Dr. Wu is using advanced retinal imaging to study how juvenile myopia and related complications damage the retina. Her work aims to improve early detection and monitoring before permanent vision loss occurs.

Dr. Wang is investigating Toxoplasma gondii, a parasite that can be acquired through contaminated food or exposure to contaminated soil or cat feces and can also be passed from mother to child during pregnancy. Her research focuses on how chronic cysts from the parasite form, persist, and reactivate in the eye, potentially leading to new treatments that prevent recurring eye damage and vision loss.

Dr. Vemula is studying the role of VEGF-A in infantile nystagmus, particularly in patients with albinism. His work could help determine whether an existing class of eye drugs may offer a new therapeutic approach.